Neurocrine’s Bad Dream Continues: Indiplon FDA Approval Requires Three More Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA “approvable” letter for the insomnia agent is particularly stinging because Neurocrine was set to announce a new commercialization agreement with a leading pharma company.